CSE: SONA | OTCQB: SNANF
   +1-902-442-0653   Purdy’s Wharf Tower II Suite 2001 – 1969 Upper Water Street

Category: News Releases

News & Media — News Releases

News Releases

Sona Nanotech to Present at the OTC Markets’ Life Sciences Virtual Investor Forum On September 17th (1)
September 11, 2026

Sona Nanotech to Present at the OTC Markets’ Life Sciences Virtual Investor Forum On September 17th
Sona Nanotech Closes Over-Subscribed Private Placement Financing to Raise $2,527,012 in Gross Proceeds (2)
August 11, 2026

Sona Nanotech Closes Over-Subscribed Private Placement Financing to Raise $2,527,012 in Gross Proceeds
Sona Nanotech To Arrange Private Placement Financing
July 31, 2026

Sona Nanotech To Arrange Private Placement Financing
Sona Nanotech Appoints Seasoned Biotech Commercial Executive Michael A. Fleming to Board of Directors (1)
June 11, 2026

Sona Nanotech Appoints Seasoned Biotech Commercial Executive Michael A. Fleming to Board of Directors
Sona Nanotech Announces Clinical Strategy With Two THT Combination Therapy Studies In Melanoma
May 5, 2026

Sona Nanotech Announces Clinical Strategy With Two THT Combination Therapy Studies In Melanoma
Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer Conferences
April 27, 2026

Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer Conferences
Sona Nanotech Announces Appointment of Two Leading Oncologists To Its Scientific Advisory Board
April 16, 2026

Sona Nanotech Announces Appointment of Two Leading Oncologists To Its Scientific Advisory Board
Sona Nanotech Clinical Cancer Study Tissue Analysis Confirms Tumor Priming And Suggests Potential Immunotherapy Synergies
April 13, 2026

Sona Nanotech Clinical Cancer Study Tissue Analysis Confirms Tumor Priming And Suggests Potential Immunotherapy Synergies
Sona Nanotech’s THT Cancer Therapy Demonstrates Strong Efficacy And Durability In Combination with Immunotherapy In Peer-reviewed Preclinical Study
April 7, 2026

Sona Nanotech’s THT Cancer Therapy Demonstrates Strong Efficacy And Durability In Combination with Immunotherapy In Peer-reviewed Preclinical Study
Sona Nanotech To Hold Investor Webinar To Discuss Follow-up Data From First-in-human Cancer Therapy Study
March 16, 2026

Sona Nanotech To Hold Investor Webinar To Discuss Follow-up Data From First-in-human Cancer Therapy Study
Load More
Subscribe